Oruka Therapeutics, Inc. financial data

Symbol
ORKA, ABIO on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
855 Oak Grove Ave., Suite 100, Menlo Park, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
ARCA biopharma, Inc. (to 8/30/2024), NUVELO INC (to 1/27/2009), HYSEQ INC (to 1/28/2003)
Latest financial report
10-Q - Q2 2024 - Aug 1, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.28K % +14.7%
Debt-to-equity 3.44 % -19.6%
Return On Equity -20.2 % -30.8%
Return On Assets -19.5 % -31.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.5M shares +0.67%
Common Stock, Shares, Outstanding 14.5M shares +0.67%
Entity Public Float 20.9M USD -28.3%
Common Stock, Value, Issued 14K USD 0%
Weighted Average Number of Shares Outstanding, Basic 14.5M shares +0.67%
Weighted Average Number of Shares Outstanding, Diluted 14.5M shares +0.67%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 664K USD -61.6%
General and Administrative Expense 8.47M USD +37.9%
Operating Income (Loss) -9.13M USD -16%
Net Income (Loss) Attributable to Parent -7.2M USD -13.7%
Earnings Per Share, Basic -0.5 USD/shares -16.3%
Earnings Per Share, Diluted -0.5 USD/shares -16.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33.3M USD -17.1%
Other Assets, Current 537K USD -10.4%
Assets, Current 33.8M USD -17%
Property, Plant and Equipment, Net 4K USD -76.5%
Operating Lease, Right-of-Use Asset 8K USD -97.3%
Other Assets, Noncurrent 12K USD -33.3%
Assets 33.8M USD -17.6%
Accounts Payable, Current 571K USD +137%
Employee-related Liabilities, Current 109K USD -42.6%
Liabilities, Current 1.27M USD -20.7%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 1.27M USD -31.1%
Retained Earnings (Accumulated Deficit) -193M USD -3.87%
Stockholders' Equity Attributable to Parent 32.6M USD -17%
Liabilities and Equity 33.8M USD -17.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.53M USD +4.2%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 14.5M shares +0.67%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.53M USD +4.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 33.3M USD -17.1%
Deferred Tax Assets, Valuation Allowance 55.5M USD +2.13%
Deferred Tax Assets, Gross 55.6M USD +2.08%
Operating Lease, Liability 24K USD -92.7%
Payments to Acquire Property, Plant, and Equipment 2K USD -66.7%
Lessee, Operating Lease, Liability, to be Paid 25K USD -93.3%
Property, Plant and Equipment, Gross 222K USD -3.06%
Operating Lease, Liability, Current 24K USD -72.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 96K USD +3.23%
Lessee, Operating Lease, Liability, to be Paid, Year One 93K USD -26.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1K USD -97.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 100K USD +4.17%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 25K USD -75%
Operating Lease, Payments 23K USD -30.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 63K USD -29.2%
Share-based Payment Arrangement, Expense 521K USD -14.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%